Is a technology that inhibits tyrosine kinase and shows activity against all isoforms of VEGF and placental growth factor the future of wet AMD therapy? Data from the DAVIO study, which were shared at the 2021 AAO Annual meeting late-breakers session, could be of interest. David Boyer, MD, discussed the drug design of EYP-1901 (EyePoint Pharmaceuticals) and summarized the findings of the phase 1 DAVIO study, which examined the drug’s use in wet AMD patients. NRR also invited Firas Rahhal, MD, to review the safety and efficacy findings of the phase 3 NORSE-2 trial, which explored use of an ocular formation of bevacizumab (bevacizumab-vikg, Outlook Therapeutics) in patients with wet AMD. 

This editorially independent podcast is supported with advertising.